Takeda Pharmaceutical Company Ltd

Christopher Ma, Brian Feagan, Vipul Jairath, Reena Khanna, Parambir S. Dulai, and William J Sandborn disclose various financial relationships with pharmaceutical companies and research organizations, including grants, personal fees, and other forms of compensation, outside their submitted work. Robert Battat and Parambir S. Dulai report no conflict of interest.

FDA approved brigatinib for ALK-positive metastatic NSCLC patients unresponsive to crizotinib. Brigatinib, part of ALK inhibitors, targets ALK mutations causing NSCLC. It showed tumor shrinkage in 48-53% of patients and brain metastasis reduction in 42-67%. Takeda must confirm clinical benefits, with ALTA 1L trial comparing brigatinib to crizotinib.

The multiple myeloma (MM) market is expected to grow significantly, driven by monoclonal antibodies elotuzumab and daratumumab. MM, a blood cancer, affects bone marrow and blood cell production. Treatments include chemotherapy, biologic therapy, and stem-cell transplant. New drugs like elotuzumab and daratumumab are anticipated to extend relapse intervals and increase treatment accessibility.